RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New universal cell therapy shows promise for Hard-to-Treat blood cancer
Disease control TerminatedThis early-stage study tested a new type of cell therapy called LUCAR-B68 in 8 adults with multiple myeloma that had come back or stopped responding to treatment. The therapy targets a protein called BCMA on cancer cells and is designed to be used without needing to match the pat…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental NK cell therapy for blood cancers hits early hurdle
Disease control TerminatedThis early-stage study tested a new drug called SAR445514, which helps the body's natural killer (NK) cells attack cancer cells in people with multiple myeloma or light-chain amyloidosis that had returned or stopped responding to other treatments. The study was terminated early, …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail shows promise for Tough-to-Treat myeloma
Disease control TerminatedThis study tested a combination of four drugs (daratumumab, ixazomib, pomalidomide, and dexamethasone) in 23 people with multiple myeloma that had come back or stopped responding to earlier treatments. The goal was to see how many patients' tumors shrank or disappeared. The study…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental myeloma drug AMG 701 trial halted early
Disease control TerminatedThis study tested an experimental drug called AMG 701, alone or with other medicines, in 174 adults with multiple myeloma that returned or didn't respond to prior treatments. The main goals were to check safety and find the best dose. The trial was stopped early, so results are l…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC